Necessity of antiviral treatment for patients with chronic hepatitis B in the grey zone based on liver pathology analysis

doi:10.1080/07853890.2024.2399757

科研成果详情

题名	Necessity of antiviral treatment for patients with chronic hepatitis B in the grey zone based on liver pathology analysis
作者	Zhang, Jianna1; Yu, Sijie 2; Zhu, Kailu 3; Li, Shibo2; Huang, Yu4
发表日期	2024-12-31
发表期刊	ANNALS OF MEDICINE 影响因子和分区
语种	英语
原始文献类型	Article
关键词	Chronic hepatitis B grey zone Ishak liver biopsy
摘要	Objective28-55% of chronic hepatitis B (CHB) patients belong to the grey zone (GZ). By analyzing the pathological characteristics of the liver of patients in the GZ, this study clarified whether the patients in the GZ need anti-hepatitis B virus treatment.MethodWe reviewed 324 cases of liver pathology that underwent liver biopsy between 2011 and 2022. According to the total score of inflammation G, 0-6 points are classified as mild, 7-12 points are classified as moderate, and 13-18 points are classified as severe. According to the total score of fibrosis F, 0-2 is mild, 3-4 is moderate, and 5-6 is severe. Significant histological diseases (SHD) are defined as the presence of inflammation G >= 6 and/or fibrosis F >= 2 in liver biopsy specimens.Result324 GZ patients were scored using the Ishak method, with G7-18 accounting for 9%, F3-6 accounting for 19.2%, and SHD accounting for 37%. The inflammation, fibrosis, and SHD in the HBeAg (+) group were more pronounced than those in the HBeAg (-) group. Among the GZ-A similar to GZ-D subgroups, the highest proportion of SHD in the GZ-B group was 58.35%.ConclusionMore than 1/3 of the patients in GZ need anti-hepatitis B virus treatment. More than half of GZ-B patients need anti-hepatitis B virus treatment. It is very necessary to carry out rescue anti-hepatitis B virus treatment for patients in GZ as soon as possible.
资助项目	Zhejiang Province Major Science and Technology Project for Medicine and Health [WKJ-ZJ-2329]; Public Welfare Science and Technology Project of Wenzhou [Y2020267]
出版者	TAYLOR & FRANCIS LTD
ISSN	0785-3890
EISSN	1365-2060
卷号	56 期号:1
DOI	10.1080/07853890.2024.2399757
页数	9
WOS类目	Medicine, General & Internal
WOS研究方向	General & Internal Medicine
WOS记录号	WOS:001313903100001
收录类别	SCIE ; PUBMED
URL	查看原文
PubMed ID	39283046
通讯作者地址	[Huang, Yu]Wenzhou Med Univ, Affiliated Hosp 1, Dept Infect Dis, Wenzhou 325000, Peoples R China.
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/218724
专题	附属第一医院附属第一医院_肾内科其他_附属舟山医院（舟山医院）
通讯作者	Huang, Yu
作者单位	1.Wenzhou Med Univ, Affiliated Hosp 1, Dept Nephrol, Wenzhou, Peoples R China; 2.Wenzhou Med Univ, Zhoushan Hosp, Dept Infect Dis, Zhoushan, Peoples R China; 3.Taizhou First Peoples Hosp, Dept Infect Dis, Taizhou, Peoples R China; 4.Wenzhou Med Univ, Affiliated Hosp 1, Dept Infect Dis, Wenzhou 325000, Peoples R China
第一作者单位	附属第一医院; 肾内科
通讯作者单位	附属第一医院
第一作者的第一单位	附属第一医院
推荐引用方式 GB/T 7714	Zhang, Jianna,Yu, Sijie,Zhu, Kailu,et al. Necessity of antiviral treatment for patients with chronic hepatitis B in the grey zone based on liver pathology analysis[J]. ANNALS OF MEDICINE,2024,56(1).
APA	Zhang, Jianna, Yu, Sijie, Zhu, Kailu, Li, Shibo, & Huang, Yu. (2024). Necessity of antiviral treatment for patients with chronic hepatitis B in the grey zone based on liver pathology analysis. ANNALS OF MEDICINE, 56(1).
MLA	Zhang, Jianna,et al."Necessity of antiviral treatment for patients with chronic hepatitis B in the grey zone based on liver pathology analysis".ANNALS OF MEDICINE 56.1(2024).